Armistice Capital, LLC Reports New 9.99% Passive Stake in Calidi Biotherapeutics (CLDI)

On May 15, 2026, Armistice Capital, LLC and its managing member, Steven Boyd, filed a Schedule 13G disclosing a new 9.99% stake in Calidi Biotherapeutics, Inc. (CLDI). The reporting persons reported beneficial ownership of 1,111,732 shares of common stock as of the event date of March 31, 2026. Armistice Capital, LLC serves as the investment manager for Armistice Capital Master Fund Ltd., which is the direct holder of the shares. Under the terms of their Investment Management Agreement, Armistice Capital exercises shared voting and dispositive power over the securities. Steven Boyd, by virtue of his position as managing member of Armistice Capital, may also be deemed to beneficially own the shares. The filing indicates that the securities were acquired in the ordinary course of business and not for the purpose of influencing or changing control of the issuer. This position represents a significant new holding for the investment firm in the San Diego-based biotechnology company.